Drugs / Risankizumab
Risankizumab
also known as
RZB · Skyrizi · BI 655066 · ABBV-066 · RISA · Risakizumab · risankizumab-800CW · risankizumab-rzaa
Regulatory milestones approvals, filings & regulatory actions · 11 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (9) | US (FDA) | SKYRIZI | — | 2021-04-26 – 2026-06-26 | fda.gov ↗ |
| Approved | EU (EMA) | Skyrizi | — | 2019-04-26 | europa.eu ↗ |
| Approved | US (FDA) | SKYRIZI | — | 2019-04-23 | fda.gov ↗ |
Trials 80 · started per year
today
US approved 2019
EU approved 2019
1
4
3
8
7
7
8
8
6
4
4
7
8
5
20122013201420152016201720182019202020212022202320242025202620272028
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 119 trials | ||||||
| Phase 1 | NCT07466550 | Jun 2026 → Jan 2027 expected | — | AbbVie | Recruiting | No outcome recorded |
| Phase 1 | NCT07007091 | Jun 2025 → Jan 2026 | — | AbbVie | Completed | No outcome recorded |
| Phase 1 | NCT06946524 | May → Nov 2025 | — | AbbVie | Completed | No outcome recorded |
| Phase 1 | NCT06937619 | Apr → Nov 2025 | — | AbbVie | Completed | No outcome recorded |
| Phase 1 | NCT06571266 | Sep 2024 → Apr 2025 | — | AbbVie | Completed | No outcome recorded |
| Phase 1 | NCT06487572 | Jul 2024 → Feb 2025 | — | AbbVie | Completed | No outcome recorded |
| Phase 1 | NCT06054425 | Nov 2023 → May 2024 | — | AbbVie | Completed | No outcome recorded |
| Phase 1 | NCT05567029 | Sep 2022 → Apr 2023 | — | AbbVie | Completed | No outcome recorded |
| Phase 1 | NCT05083078 | Nov 2021 → Jul 2022 | psoriatic arthritis | Janssen Research & Development, LLC | Terminated | No outcome recorded |
| Phase 1 | NCT05274087 | Sep 2020 → Apr 2021 | — | AbbVie | Completed | No outcome recorded |
| Phase 1 | NCT05274100 | Sep 2020 → Jul 2021 | — | AbbVie | Completed | No outcome recorded |
| Phase 1 | NCT04254783 | May 2020 → Oct 2022 | Crohn disease, ulcerative colitis | AbbVie | Completed | No outcome recorded |
| Phase 1 | NCT05268068 | Jun 2019 → Apr 2020 | — | AbbVie | Completed | No outcome recorded |
| Phase 1 | NCT05283681 | Apr → Nov 2019 | — | AbbVie | Completed | No outcome recorded |
| Phase 1 | NCT05305222 | Oct 2017 → Jun 2018 | — | AbbVie | Completed | No outcome recorded |
| Phase 1 | NCT05283694 | Sep 2017 → Jun 2018 | — | AbbVie | Completed | No outcome recorded |
| Phase 1 | NCT02772601 | Sep 2016 → Jun 2017 | psoriasis | AbbVie | Completed | No outcome recorded |
| Phase 1 | NCT02596217 | Aug 2015 → Jun 2017 | — | AbbVie | Completed | No outcome recorded |
| Phase 1 | NCT01577550 | Apr 2012 → Oct 2013 | psoriasis | AbbVie | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07258641 | Jan 2026 → Dec 2027 expected | Crohn disease, ulcerative colitis | University Medical Center Groningen | Not yet recruiting | No outcome recorded |
| Phase 217 trials | ||||||
| Phase 2 | NCT07697456 | Jul 2026 → Oct 2031 expected | Crohn disease, ulcerative colitis | AbbVie | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07138898 | Dec 2025 → Jan 2028 expected | rheumatic disorder | NYU Langone Health | Recruiting | No outcome recorded |
| Phase 2 | NCT06865105 | Apr 2025 → Dec 2027 expected | psoriatic arthritis | AbbVie | Recruiting | No outcome recorded |
| Phase 2 | NCT06548542 | Sep 2024 → Jan 2030 expected | Crohn disease | AbbVie | Recruiting | No outcome recorded |
| Phase 2 | NCT05283135 | Mar 2022 → Aug 2023 | psoriasis | Oregon Medical Research Center | Completed | No outcome recorded |
| Phase 2 | NCT04583956 | Oct 2020 → Sep 2021 | COVID-19 | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 2 | NCT03926169 | Jun 2019 → Feb 2021 | hidradenitis suppurativa | AbbVie | Completed | No outcome recorded |
| Phase 2 | NCT03706040 | Dec 2018 → Oct 2020 | atopic eczema | AbbVie | Completed | No outcome recorded |
| Phase 2 | NCT02986373 | Dec 2016 → Jul 2018 | psoriatic arthritis | AbbVie | Completed | No outcome recorded |
| Phase 2 | NCT03000075 | Dec 2016 → Sep 2017 | psoriasis | AbbVie | Completed | No outcome recorded |
| Phase 2 | NCT02719171 | Apr 2016 → May 2017 | psoriatic arthritis | AbbVie | Completed | No outcome recorded |
| Phase 2 | NCT02513459 | Sep 2015 → Jun 2019 | Crohn disease | AbbVie | Completed | No outcome recorded |
| Phase 2 | NCT02443298 | Jun 2015 → Oct 2017 | asthma | AbbVie | Completed | No outcome recorded |
| Phase 2 | NCT02203851 | Nov 2014 → Sep 2018 | psoriasis | AbbVie | Completed | No outcome recorded |
| Phase 2 | NCT02054481 | Feb → Nov 2014 | psoriasis | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 2 | NCT02031276 | Feb 2014 → Dec 2015 | Crohn disease | AbbVie | Completed | No outcome recorded |
| Phase 2 | NCT02047110 | Jan 2014 → Mar 2015 | ankylosing spondylitis | AbbVie | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT03398148 | Mar 2018 → Nov 2022 | ulcerative colitis | AbbVie | Completed | No outcome recorded |
| Phase 330 trials | ||||||
| Phase 3 | NCT07499232 | Apr 2026 → Nov 2028 expected | Crohn disease | Janssen Research & Development, LLC | Recruiting | No outcome recorded |
| Phase 3 | NCT07177118 | Oct 2025 → Jun 2028 expected | Crohn disease | First Affiliated Hospital of Wenzhou Medical University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07071519 | Jul 2025 → Jul 2034 expected | ulcerative colitis | AbbVie | Recruiting | No outcome recorded |
| Phase 3 | NCT06100744 | Jul 2024 → Sep 2026 expected | psoriasis-related juvenile idiopathic arthritis | AbbVie | Recruiting | No outcome recorded |
| Phase 3 | NCT05995353 | Dec 2023 → Apr 2029 expected | Crohn disease | AbbVie | Recruiting | No outcome recorded |
| Phase 3 | NCT06063967 | Nov 2023 → Mar 2027 expected | Crohn disease | AbbVie | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04862286 | Jul 2021 → Apr 2028 expected | psoriasis | AbbVie | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04713592 | Feb 2021 → Apr 2023 | psoriasis | AbbVie | Completed | No outcome recorded |
| Phase 3 | NCT04524611 | Sep 2020 → Feb 2028 expected | Crohn disease | AbbVie | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04451720 | Jul 2020 → Nov 2022 | palmoplantar pustulosis | AbbVie | Completed | No outcome recorded |
| Phase 3 | NCT04435600 | Jul 2020 → Feb 2024 | psoriasis | AbbVie | Completed | No outcome recorded |
| Phase 3 | NCT04102007 | Nov 2019 → Jan 2022 | psoriasis | AbbVie | Completed | No outcome recorded |
| Phase 3 | NCT03875508 | Jun 2019 → Apr 2020 | psoriasis | AbbVie | Completed | No outcome recorded |
| Phase 3 | NCT03875482 | May 2019 → Feb 2020 | psoriasis | AbbVie | Completed | No outcome recorded |
| Phase 3 | NCT03675308 | Mar 2019 → Oct 2020 overdue | psoriatic arthritis | AbbVie | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03671148 | Mar 2019 → Jun 2020 | psoriatic arthritis | AbbVie | Completed | No outcome recorded |
| Phase 3 | NCT03398135 | Aug 2018 → Sep 2028 expected | ulcerative colitis | AbbVie | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03219437 | Jul 2018 → Nov 2021 | psoriasis | AbbVie | Completed | No outcome recorded |
| Phase 3 | NCT03518047 | Jul 2018 → Feb 2020 | psoriasis | AbbVie | Completed | No outcome recorded |
| Phase 3 | NCT03478787 | May 2018 → Jul 2020 | psoriasis | AbbVie | Completed | No outcome recorded |
| Phase 3 | NCT03105102 | Apr 2018 → May 2026 overdue | Crohn disease | AbbVie | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03104413 | Dec 2017 → Nov 2020 | Crohn disease | AbbVie | Completed | No outcome recorded |
| Phase 3 | NCT03255382 | Aug 2017 → Jul 2018 | psoriasis | AbbVie | Completed | No outcome recorded |
| Phase 3 | NCT03105128 | May 2017 → Nov 2020 | Crohn disease | AbbVie | Completed | No outcome recorded |
| Phase 3 | NCT03047395 | Feb 2017 → Nov 2023 | psoriasis | AbbVie | Completed | No outcome recorded |
| Phase 3 | NCT03022045 | Jan → Sep 2017 | psoriasis | AbbVie | Completed | No outcome recorded |
| Phase 3 | NCT02684357 | Mar → Dec 2016 | psoriasis | AbbVie | Completed | No outcome recorded |
| Phase 3 | NCT02694523 | Mar 2016 → Aug 2017 | psoriasis | AbbVie | Completed | No outcome recorded |
| Phase 3 | NCT02672852 | Feb 2016 → Aug 2017 | psoriasis | AbbVie | Completed | No outcome recorded |
| Phase 3 | NCT02684370 | Feb → Dec 2016 | psoriasis | AbbVie | Completed | No outcome recorded |
| Phase 411 trials | ||||||
| Phase 4 | NCT07352566 | Aug 2026 → Jun 2030 expected | atopic eczema, psoriasis | University of California, San Francisco | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07149792 | Jul 2025 → Dec 2026 expected | psoriasis, psoriatic arthritis | Taichung Veterans General Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT06333860 | May 2024 → Mar 2026 | psoriasis | AbbVie | Completed | No outcome recorded |
| Phase 4 | NCT06346288 | Apr 2024 → Feb 2026 | inflammatory bowel disease | AbbVie | Completed | No outcome recorded |
| Phase 4 | NCT05969223 | Aug 2023 → Jan 2025 | psoriasis | AbbVie | Completed | No outcome recorded |
| Phase 4 | NCT05270733 | Nov 2022 → Dec 2026 expected | psoriasis | University Hospitals Cleveland Medical Center | Recruiting | No outcome recorded |
| Phase 4 | NCT05169593 | Sep 2022 → Oct 2027 expected | Crohn disease | Universitaire Ziekenhuizen KU Leuven | Recruiting | No outcome recorded |
| Phase 4 | NCT04908475 | Jun 2021 → Apr 2023 | psoriasis | AbbVie | Completed | No outcome recorded |
| Phase 4 | NCT04630652 | Apr 2021 → May 2025 | psoriasis | Jaehwan Kim | Completed | No outcome recorded |
| Phase 4 | NCT04722640 | Jan 2021 → Jan 2022 | psoriasis | Istituto Clinico Humanitas | Unknown | No outcome recorded |
| Phase 4 | NCT04340076 | Aug 2020 → Jan 2025 | psoriasis | Radboud University Medical Center | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT06298188 | Oct 2024 → Oct 2026 expected | Crohn disease | Shaare Zedek Medical Center | Recruiting | No outcome recorded |
Also used as a comparator or background therapy in 8 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07258745 Comparator | Nov 2025 → Sep 2026 expected | psoriasis | Chong Kun Dang Pharmaceutical | Recruiting | No outcome recorded |
| Phase 35 trials | ||||||
| Phase 3 | NCT06880744 Comparator | Jun 2025 → Aug 2027 expected | ulcerative colitis | AbbVie | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06624228 Comparator | Oct 2024 → Feb 2026 | psoriatic arthritis | UCB Biopharma SRL | Completed | No outcome recorded |
| Phase 3 | NCT06641089 Comparator | Oct 2024 → Jan 2027 expected | psoriatic arthritis | MoonLake Immunotherapeutics AG | Recruiting | No outcome recorded |
| Phase 3 | NCT06274554 Background | Oct 2024 → Dec 2028 expected | Crohn disease | Weill Medical College of Cornell University | Recruiting | No outcome recorded |
| Phase 3 | NCT04505410 Comparator | Sep 2020 → Dec 2023 | ulcerative colitis | University of Miami | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT05928039 Comparator | Oct 2023 → Jul 2027 expected | Crohn disease | University of Calgary | Recruiting | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT03914261 Background | — | Crohn disease, ulcerative colitis | AbbVie | No longer available | No outcome recorded |
Press releases naming this drug 49 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-06-26 | AbbVie | SKYRIZI® (risankizumab-rzaa) Now FDA Approved for Pediatric Use in Psoriatic Disease abbvie.com ↗ |
| 2026-06-23 | AbbVie | AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis abbvie.com ↗ |
| 2026-04-27 | AbbVie | AbbVie Submits Regulatory Application to FDA for SKYRIZI® (risankizumab-rzaa) Subcutaneous Induction for Adults with Moderately to Severely Active Crohn's Disease abbvie.com ↗ |
| 2026-03-02 | AbbVie | AbbVie Announces Positive Topline Results from Phase 3 AFFIRM Study Evaluating SKYRIZI® (Risankizumab) Subcutaneous Induction in Patients with Crohn's Disease abbvie.com ↗ |
| 2024-07-26 | AbbVie | AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis abbvie.com ↗ |
| 2024-06-18 | AbbVie | U.S. FDA Approves SKYRIZI® (risankizumab-rzaa) for Ulcerative Colitis, Expanding AbbVie's Portfolio Across Inflammatory Bowel Disease abbvie.com ↗ |
| 2024-05-31 | AbbVie | AbbVie Receives Positive CHMP Opinion for Risankizumab (SKYRIZI®) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis abbvie.com ↗ |
| 2023-10-15 | AbbVie | AbbVie's SKYRIZI® (risankizumab) Versus STELARA® (ustekinumab) Head-to-Head Study in Crohn's Disease Meets All Primary and Secondary Endpoints abbvie.com ↗ |
| 2023-09-12 | AbbVie | AbbVie's SKYRIZI® (risankizumab) Met All Primary and Secondary Endpoints Versus Stelara® (ustekinumab) in Head-to-Head Study in Crohn's Disease abbvie.com ↗ |
| 2023-08-28 | AbbVie | AbbVie Submits Regulatory Applications to FDA and EMA for Risankizumab (SKYRIZI®) in Ulcerative Colitis abbvie.com ↗ |
| 2023-07-26 | AbbVie | SKYRIZI® (risankizumab) Achieved Superiority Versus Apremilast for Co-Primary Endpoints Among Adult Patients with Moderate Plaque Psoriasis in Phase 4 Head-to-Head Study abbvie.com ↗ |
| 2023-06-15 | AbbVie | Risankizumab (SKYRIZI®) Met Primary and Key Secondary Endpoints in 52-Week Phase 3 Maintenance Study in Ulcerative Colitis Patients abbvie.com ↗ |
| 2023-03-23 | AbbVie | Risankizumab (SKYRIZI®) Achieves Primary and All Secondary Endpoints in Phase 3 Induction Study in Patients With Ulcerative Colitis abbvie.com ↗ |
| 2023-03-18 | AbbVie | AbbVie Announces Late-Breaking Results of Study Evaluating 52-Week Efficacy and Safety of SKYRIZI® (risankizumab) in Plaque Psoriasis Patients With a Prior Suboptimal Response to IL-17 Inhibitor Therapy abbvie.com ↗ |
| 2022-11-23 | AbbVie | AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Moderate to Severe Active Crohn's Disease abbvie.com ↗ |
| 2022-09-19 | AbbVie | AbbVie Secures Positive CHMP Opinion for Risankizumab (SKYRIZI®) for the Treatment of Adults with Moderate to Severe Crohn's Disease abbvie.com ↗ |
| 2022-09-10 | AbbVie | New Late-Breaking Results from Phase 3 Trials of SKYRIZI® (risankizumab) Evaluating Long-term Effect on Skin and Joint Symptoms in Patients with Psoriatic Arthritis at Week 100 abbvie.com ↗ |
| 2022-06-17 | AbbVie | SKYRIZI® (risankizumab-rzaa) Receives FDA Approval as the First and Only Specific Interleukin-23 (IL-23) to Treat Moderately to Severely Active Crohn's Disease in Adults abbvie.com ↗ |
| 2022-05-27 | AbbVie | The Lancet Publishes Results from Phase 3 Induction and Maintenance Programs Evaluating Risankizumab (SKYRIZI®) in Crohn's Disease abbvie.com ↗ |
| 2022-02-28 | AbbVie | AbbVie Provides Update Regarding SKYRIZI® (risankizumab-rzaa) for the Treatment of Moderate to Severe Crohn's Disease in the U.S. abbvie.com ↗ |
| 2022-01-21 | AbbVie | U.S. FDA Approves Second Indication for SKYRIZI® (risankizumab-rzaa) to Treat Adults with Active Psoriatic Arthritis abbvie.com ↗ |
| 2022-01-11 | AbbVie | AbbVie Confirms Guidance of Greater Than $15 Billion in Combined Risk-Adjusted Sales for Rinvoq and Skyrizi in 2025 abbvie.com ↗ |
| 2021-11-30 | AbbVie | AbbVie Submits Application for Risankizumab (SKYRIZI®) in Moderate to Severe Crohn's Disease to European Medicines Agency (EMA) abbvie.com ↗ |
| 2021-11-17 | AbbVie | AbbVie Expands Immunology Portfolio in the European Union with the European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Adults with Active Psoriatic Arthritis abbvie.com ↗ |
| 2021-11-05 | AbbVie | AbbVie Presents Integrated Efficacy and Safety Data From Two Phase 3 Trials on Risankizumab (SKYRIZI®) in Psoriatic Arthritis at ACR Convergence 2021 abbvie.com ↗ |
| 2021-10-15 | AbbVie | AbbVie Receives CHMP Positive Opinion for Risankizumab (SKYRIZI®) for the Treatment of Adults with Active Psoriatic Arthritis in the European Union (EU) abbvie.com ↗ |
| 2021-09-30 | AbbVie | AbbVie Presents Late-Breaking Data on Risankizumab (SKYRIZI®) in Psoriatic Arthritis at the 30th European Academy of Dermatology and Venereology (EADV) Congress abbvie.com ↗ |
| 2021-09-20 | AbbVie | AbbVie Submits Regulatory Application to FDA for Risankizumab-rzaa (SKYRIZI®) for the Treatment of Patients 16 Years and Older with Moderate to Severe Crohn's Disease abbvie.com ↗ |
| 2021-08-09 | AbbVie | SKYRIZI® (risankizumab-rzaa) Now Available in the U.S. as a Single 150 mg Injection for Adults with Moderate to Severe Plaque Psoriasis abbvie.com ↗ |
| 2021-06-02 | AbbVie | Phase 3 Maintenance Results Show Patients with Crohn's Disease Receiving Risankizumab (SKYRIZI®) Achieved Endoscopic Response and Clinical Remission at One Year abbvie.com ↗ |
| 2021-05-24 | AbbVie | AbbVie Presents New Late-Breaking Data Analyses Showing Risankizumab (SKYRIZI®) Achieves Clinical Remission and Endoscopic Response at Week 12 in Patients with Moderate to Severe Crohn's Disease abbvie.com ↗ |
| 2021-04-07 | AbbVie | AbbVie Submits Regulatory Applications for SKYRIZI® (risankizumab) in Psoriatic Arthritis to FDA and EMA abbvie.com ↗ |
| 2021-01-07 | AbbVie | Risankizumab (SKYRIZI®) Demonstrates Significant Improvements in Clinical Remission and Endoscopic Response in Two Phase 3 Induction Studies in Patients with Crohn's Disease abbvie.com ↗ |
| 2021-01-05 | AbbVie | Risankizumab (SKYRIZI®) Phase 3 Results Demonstrate Improvements in Disease Activity Across Joint and Skin Symptoms Among Psoriatic Arthritis Patients abbvie.com ↗ |
| 2020-06-12 | AbbVie | AbbVie Presents New Late-Breaking Data Showing SKYRIZI® (risankizumab-rzaa) Achieves Superior Rates of Complete Skin Clearance Versus COSENTYX® (secukinumab) at 52 Weeks abbvie.com ↗ |
| 2020-01-14 | AbbVie | New Head-to-Head Phase 3 Data Show SKYRIZI™ (risankizumab) Superior to Cosentyx® (secukinumab) Across Primary and All Ranked Secondary Endpoints in Adults with Moderate to Severe Plaque Psoriasis at 52 Weeks abbvie.com ↗ |
| 2019-06-11 | AbbVie | New Two-Year Data at the 24th World Congress of Dermatology Shows SKYRIZI™ (risankizumab) Maintains Complete Skin Clearance abbvie.com ↗ |
| 2019-04-30 | AbbVie | European Commission Approves SKYRIZI™ (risankizumab) for the Treatment of Moderate to Severe Plaque Psoriasis abbvie.com ↗ |
| 2019-04-23 | AbbVie | AbbVie Expands Immunology Portfolio in the U.S. with FDA Approval of SKYRIZI™ (risankizumab-rzaa) for Moderate to Severe Plaque Psoriasis abbvie.com ↗ |
| 2019-03-26 | AbbVie | AbbVie Announces First Regulatory Approval of SKYRIZI™ (risankizumab) for the Treatment of Plaque Psoriasis, Generalized Pustular Psoriasis and Erythrodermic Psoriasis and Psoriatic Arthritis in Japan abbvie.com ↗ |
| 2019-03-01 | AbbVie | AbbVie Receives CHMP Positive Opinion for Risankizumab (SKYRIZI™) for the Treatment of Moderate to Severe Plaque Psoriasis abbvie.com ↗ |
| 2018-09-13 | AbbVie | AbbVie Announces Patient-Reported Outcomes Data from Three Pivotal Phase 3 Studies of Risankizumab, Showing Significant Improvements in Health-Related Quality of Life for Patients with Psoriasis abbvie.com ↗ |
| 2018-05-01 | AbbVie | AbbVie Submits Marketing Authorization Application to the European Medicines Agency for Investigational Treatment Risankizumab for Moderate to Severe Plaque Psoriasis abbvie.com ↗ |
| 2018-04-25 | AbbVie | AbbVie Submits Biologics License Application to U.S. FDA for Investigational Treatment Risankizumab for Moderate to Severe Plaque Psoriasis abbvie.com ↗ |
| 2018-02-17 | AbbVie | AbbVie Presents New Positive Late-Breaking Data from Two Phase 3 Psoriasis Trials of Risankizumab at the 2018 American Academy of Dermatology Annual Meeting abbvie.com ↗ |
| 2017-12-04 | AbbVie | Risankizumab Meets All Primary Endpoints Reporting Positive Results in Fourth Pivotal Phase 3 Psoriasis Study abbvie.com ↗ |
| 2017-10-26 | AbbVie | Risankizumab Meets All Co-Primary and Ranked Secondary Endpoints, Achieving Significantly Greater Efficacy Versus Standard Biologic Therapies in Three Pivotal Phase 3 Psoriasis Studies abbvie.com ↗ |
| 2016-11-30 | AbbVie | AbbVie Receives Orphan Drug Designation for Investigational IL-23 Inhibitor Risankizumab from the U.S. Food and Drug Administration for the Treatment of Pediatric Patients with Crohn's Disease abbvie.com ↗ |
| 2016-05-24 | AbbVie | IL-23 Inhibitor Risankizumab Induces Remission in Phase II Study in Patients with Moderate-to-Severe Crohn's Disease abbvie.com ↗ |
Evidence & citations 12 cited values
Every value below carries the sentence it was read from. 95 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | risankizumab | “Patients will be treated with ustekinumab (90mg at week 0 and week 4 by subcutaneous injection) for 8 weeks followed by treatment with guselkumab (100mg at week 0 and week 4 by...” NCT05270733 ↗83“risankizumab (BI 655066), a humanized IgG1 monoclonal antibody that inhibits interleukin-23 by specifically targeting the p19 subunit and thus prevents interleukin-23 signaling” PMID 28423301 ↗ Apr 2017 “Risankizumab: Induction with 600 mg IV at day 0, week 4 and week 8; maintenance with 360 mg SC at week 12 and every eight weeks thereafter.” NCT05169593 ↗ “new advanced therapy: Tofacitinib and Upadacitinib (JAK inhibitors), Infliximab (anti-TNF), Ustekinumab or Risankizumab (IL-23 inhibitors).” NCT04505410 ↗ “IL-23 therapy may include ustekinumab (anti-interleukin-12/23), risankizumab (anti-interleukin-23), or guselkumab (anti-interleukin-23).” NCT06274554 ↗ “S. pyogenes + risankizumab (2 μg/mL)” NCT07149792 ↗ |
| Known as | ABBV-066 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02596217 ↗ |
| Known as | BI 655066 | “risankizumab (BI 655066), a humanized IgG1 monoclonal antibody that inhibits interleukin-23 by specifically targeting the p19 subunit and thus prevents interleukin-23 signaling” PMID 28423301 ↗ Apr 2017 |
| Known as | RISA | “Patients were classified into five cohorts on the basis of their treatment experience during the follow-up period: risankizumab (RISA) only, RISA followed by re-randomization...” PMID 34921669 ↗ Dec 2021 |
| Known as | Risakizumab | “Patients whose lymphocytes reacted with proliferation to LL37 or ADAMTSL5 will receive SKYRIZI (Risakizumab) at Day 1, week 4, 16, 28, 40.” NCT04722640 ↗ |
| Known as | risankizumab-800CW | “fluorescently labeled adalimumab (adalimumab-680LT) and risankizumab (risankizumab-800CW)” NCT07258641 ↗ |
| Known as | risankizumab-rzaa | “In this study, subjects with moderate-to-severe psoriasis will receive FDA-approved anti-IL-23p19 antibody (Generic name: Risankizumab, Product name: SKYRIZI™ or...” NCT04630652 ↗ |
| Known as | RZB | “OBJECTIVES: Determine the impact of 24-week risankizumab (RZB) versus placebo (PBO) on patient-reported outcomes (PROs) in patients with psoriatic arthritis (PsA) and...” PMID 35701011 ↗ Jun 20223“This post hoc analysis evaluated the corticosteroid-sparing effects of risankizumab (RZB) therapy in patients with moderate-to-severe ulcerative colitis in the phase 3...” PMID 40168091 ↗ Apr 2025 “Risankizumab (RZB) and deucravacitinib (DEU) are both approved for the treatment of moderate-to-severe psoriasis.” PMID 42143644 ↗ May 2026 “To evaluate the long-term efficacy and safety of risankizumab (RZB) for the treatment of psoriasis.” PMID 34157132 ↗ Sep 2021 |
| Known as | Skyrizi | “EU-approved Skyrizi®, and US-licensed Skyrizi®” NCT07258745 ↗ |
| Action | Inhibit | “Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis” PMID 29945918 ↗ Jun 2018 |
| Modality | Monoclonal antibody | “anti-interleukin (IL)-23 monoclonal antibody” PMID 31054118 ↗ Oct 2019 |
| Route | Intravenous | “risankizumab administered by IV infusion” NCT02031276 ↗ |